JPRN-UMIN000002783
Completed
未知
A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutations - A phase II study of gefitinib as first-line treatment for elderly patients with advanced lung adenocarcinoma who have active EGFR mutations
agano lung cancer study meeting0 sites15 target enrollmentNovember 19, 2009
Conditionslung adenocarcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- lung adenocarcinoma
- Sponsor
- agano lung cancer study meeting
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)interstitial pneumonia on computed tomography scan 2\)liver cirrhosis, uncontrolled diabetes mellitus, cardiac infarciton and cereral apoplexy onset within three months 3\)othere active cancer 4\)symptomatic brain metastases 5\)need to plan the radiotherapy included in the lung field 6\)history of sever drug allegy 7\)judged to be inappropriate by the attending doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
phase II study of gefitinib as a first-line therapy in elderly patients with lung adenocarcinoma.JPRN-C000000136West Japan Oncology Group30
Completed
Phase 2
A Phase II study of Gefitinib as First-Line Treatment for Elderly Patients with Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.on-Small-Cell Lung CancerJPRN-UMIN000001863Central Japan Lung Study Group19
Completed
Phase 2
A phase II study of first-line gefitinib for advanced and recurrent EGFR mutation positivenon-small cell lung cancerwith high-risk factorsnon-small cell lung cancerJPRN-UMIN000004822Kanagawa Cancer Center37
Recruiting
Phase 1
A Phase I/II trial to evaluate gefitinib and concurrent postoperative chemoradiation in patients with advanced resectable head and neck cancerACTRN12605000510640peter maccallum Cancer Centre70
Completed
Phase 2
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutationon-small cell lung cancerJPRN-UMIN000005086ung Oncology Group in Kyushu, Japan (LOGIK)21